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Stromal Caveolin-1 Predicts Breast Cancer
Prognosis
Caveolin-1 plays a major role in breast cancer tumorigen-
esis; however, the value of epithelial caveolin-1 as a prog-
nostic marker has been limited. Witkiewicz et al (Am J
Pathol 174:2023–2034) and Sloan et al (Am J Pathol 174:
2035–2043) therefore examined caveolin-1 expression in
the stromal microenvironment of human breast cancer.
Stromal expression of caveolin-1 correlated with reduced
levels of metastasis, and caveolin-1 was not expressed in
stroma of patients with poor clinical outcome. In addition,
tumor onset in mice was accelerated in the absence of
stromal caveolin-1. Caveolin-1 may therefore function as a
tumor suppressor in the stromal microenvironment and
serve as a new prognostic marker for breast cancer pro-
gression. These data are further highlighted in the accom-
panying Commentary (Am J Pathol 174: 1996–1999).
Novel Markers for Kidney Disease Progression
Only a minority of patients with chronic kidney disease
progress to end-stage renal disease. Current clinical
markers are not sufficient to reliably predict chronic kid-
ney disease progression, which impedes targeted treat-
ment of high-risk patients. Using the heterogeneous
TGF-1 transgenic mouse model of renal disease pro-
gression, Ju et al (Am J Pathol 174:2073–2085) applied
transcriptional profiling to identify genes whose expres-
sion correlated with renal disease severity. They found
that human orthologs of a subset of these candidates
were associated with disease progression and glomeru-
lar filtration rate in human patients. These genes may
therefore serve as novel markers for chronic kidney dis-
ease progression.
Urokinase Plasminogen Activator Receptor in
Hyperoxia-Induced Lung Injury
Prolonged administration of high levels of supplemental
oxygen, hyperoxia, can often effectively treat patients
with respiratory failure. Hyperoxia, however, can induce
or exacerbate lung injury in a process mediated by neu-
trophil infiltration. Van Zoelen et al (Am J Pathol 174:
2182–2189) hypothesized that urokinase plasminogen
activator receptor (uPAR), which is important for leuko-
cyte migration, plays a role in hyperoxia-induced lung
injury. They found increased levels uPAR-expressing
neutrophils in lungs of hyperoxia-treated mice, as com-
pared with control mice. In addition, both neutrophil infil-
tration and lung injury were reduced in hyperoxia-treated
uPAR-deficient mice. Thus, inhibiting uPAR may amelio-
rate lung injury during therapeutic oxygen administration.
Immunoregulation in Tuberculosis Lesions
Although the Th1 immune response is critical for fighting
Mycobacterium tuberculosis (Mtb) infection, cell-mediated
immune responses rarely eradicate Mtb. Instead, Mtb-
infected macrophages generate granulomas, which be-
come sites of chronic inflammation. Rahman et al (Am J
Pathol 174: 2211–2224) found low numbers of perforin-
and granzyme-expressing CD8 T cells in granuloma-
tous lesions in children with local tuberculosis lymphad-
enitis; however, these granulomas contained increased
numbers of FoxP3 regulatory T cells. In addition, Mtb-
infected lymph nodes expressed high levels of the immu-
noregulatory cytokine transforming growth factor- but
low levels of the pro-inflammatory cytokines interferon-,
tumor necrosis factor-, and interleukin-17. These data
suggest that local immunoregulation may contribute to
the establishment of Mtb infection.
Synthetic Retinoic Acid Ameliorates
Autoimmunity
Th17 cells, CD4 T-helper cells that secrete IL-17, play a
pathogenic role in autoimmune diseases such as multiple
sclerosis. Using a mouse model of multiple sclerosis,
experimental autoimmune encephalitits, Klemann et al
(Am J Pathol 174: 2234–2245) found that AM80, a syn-
thetic retinoid with improved biological function over all
trans retinoic acid, inhibited Th17 cell differentiation and
effector function in vitro and in vivo, without generating
general immunosuppression. AM80 also suppressed
IL-10 expression in a Th17-like subset of regulatory T
cells. AM80 treatment was effective in inhibiting early
experimental autoimmune encephalitits symptoms, even
if administered after disease initiation, but it did not pre-
vent chronic symptoms. Therefore, AM80 is a promising
therapy for the treatment of multiple sclerosis and other
Th17-mediated autoimmune diseases.
Phagocytosis without Disrupting the
Blood-Retinal Barrier
Phagocytic cells remove damaged photoreceptors fol-
lowing retinal injury; however, the blood-retinal barrier is
thought to prevent access of inflammatory cells into the
The American Journal of Pathology, Vol. 174, No. 6, June 2009
Copyright © American Society for Investigative Pathology
DOI: 10.2353/ajpath.2009.090277
1983
eye. To identify the source of the phagocytic cells that
respond to retinal injury, Joly et al (Am J Pathol 174:
2310–2323) used a mouse model of light-induced pho-
todamage with either fluorescently labeled bone marrow-
derived cells or microglia. They found that both bone
marrow- and microglia-derived macrophages were in-
volved in the phagocytosis of dead photoreceptors. Bone
marrow-derived macrophages focused on the site of the
injury, whereas microglia were activated in the entire
retina of the light-exposed eye. Bone marrow-derived
macrophages migrated into the eye without damaging
the blood-retinal barrier, and both bone marrow- and
microglia-derived macrophages entered the circulation
following photoreceptor phagocytosis. Macrophages
laden with retinal antigen may then contribute to retinal
autoimmunity following injury.
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